Pralatrexate effectively inhibits the replication of monkeypox virus in vitro and in vivo

IF 4.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Antiviral research Pub Date : 2025-07-11 DOI:10.1016/j.antiviral.2025.106232

Jianshu Li , Siyu Li , Chaode Gu , Shaowen Shi , Xiao Li , Zhendong Guo , Zongzheng Zhao , Miao He , Zhiwei Wu

引用次数: 0

Abstract

The monkeypox virus (MPXV), an orthopoxvirus, has caused a number of major outbreaks and emerged as a global public health threat. Although drugs have been approved for the treatment of mpox, the efficacy and side effects remain unknown, which calls for the development of safe and effective drugs. Pralatrexate (PDX) is a fourth-generation antifolate drug with inhibitory activity against a wide range of viruses. In this study, we demonstrated the antiviral activity of PDX against MPXV in vitro and in vivo. Our results showed that PDX potently inhibited the MPXV replication at very low drug concentrations in vitro, and could significantly inhibit MPXV activity in dormice. In conclusion, this study found that PDX is an effective antiviral drug against MPXV infection, showing potential as a novel therapy for MPXV infection.

查看原文本刊更多论文

普拉特雷酯在体外和体内均能有效抑制猴痘病毒的复制。

猴痘病毒（MPXV）是一种正痘病毒，已引起多次重大疫情，并成为全球公共卫生威胁。虽然已经批准了治疗m痘的药物，但其疗效和副作用尚不清楚，这就要求开发安全有效的药物。praatrexate （PDX）是第四代抗叶酸药物，对多种病毒具有抑制活性。在本研究中，我们在体外和体内证明了PDX对MPXV的抗病毒活性。我们的研究结果表明，PDX在体外很低的药物浓度下就能有效抑制MPXV的复制，并能显著抑制MPXV在睡鼠体内的活性。综上所述，本研究发现PDX是一种有效的MPXV感染抗病毒药物，有可能成为MPXV感染的新疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antiviral research 医学-病毒学

CiteScore

17.10

自引率

3.90%

发文量

157

审稿时长

34 days

期刊介绍： Antiviral Research is a journal that focuses on various aspects of controlling viral infections in both humans and animals. It is a platform for publishing research reports, short communications, review articles, and commentaries. The journal covers a wide range of topics including antiviral drugs, antibodies, and host-response modifiers. These topics encompass their synthesis, in vitro and in vivo testing, as well as mechanisms of action. Additionally, the journal also publishes studies on the development of new or improved vaccines against viral infections in humans. It delves into assessing the safety of drugs and vaccines, tracking the evolution of drug or vaccine-resistant viruses, and developing effective countermeasures. Another area of interest includes the identification and validation of new drug targets. The journal further explores laboratory animal models of viral diseases, investigates the pathogenesis of viral diseases, and examines the mechanisms by which viruses avoid host immune responses.